Guidelines for biomarker-directed therapies in personalised medicine: Tools for assessment
Timeline: Q2, 2019 – Q3, 2020
Issue: Lack of guidance around the criteria that should be used to assess evidence for individualised/personalised clinical decisions especially linked to patient’s biomarker profile.
Purpose: Optimise treatments according to individualised patient characteristics and efficiencies.
Objectives: Development of the theoretical framework, particularly biostatical & methodological principles underpinning any guideline recommendations.
- Systematic review of current guidelines for assessing personalised EMB & for evidence re co-dependency of biomarkers & therapeutics.
- Convene two expert meetings; refining the nature and scope of the problem; to review recommendations relevant to Australian context.
- Formulate a framework for assessing co-dependency of biomarkers & therapies in CTs.
Framework for assessing co-dependency of biomarkers & therapies in CTs; guidelines and publication.